Silo Pharma to Present at Psychedelic Drug Development Conference
24 4월 2023 - 9:15PM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
that James Kuo, M.D., Vice President of R&D, will speak at the
3rd Annual Psychedelic Therapeutics and Drug Development
Conference being held May 15-16, 2023, in person, at the
Hilton San Francisco Airport Bayfront in Burlingame, CA.
Dr. Kuo’s presentation, titled ‘The Ketamine Endgame,’ will be
delivered on May 15, 2023 at 1:05 p.m. PDT. In his remarks about
his talk, Dr. Kuo stated, “Recently, a New York Times headline
described ketamine as a ‘cure,’ a word not often used for medical
therapies. Lots of people with treatment-resistant depression,
anxiety, and pain will surely be impacted by ketamine.”
Three of Silo Pharma’s five novel drug candidates currently
under development utilize ketamine as a primary therapeutic
agent:
- The Company recently announced positive results for a
toxicology study of SP-26, a novel time-released, dosage-controlled
formulation of ketamine indicated for fibromyalgia.
- SPC-14, a novel drug that combines an FDA-approved therapeutic
with ketamine, is in development for the treatment of dementia
related to Alzheimer's disease. A dosing study of SPC-14
demonstrated efficacy for increasing memory function.
- SPC-15, a novel formulation including ketamine as a targeted
prophylactic treatment, is intended for stress, anxiety, and
PTSD.
About the 3rd Annual Psychedelic
Therapeutics and Drug Development Conference
The conference will bring together the world’s leading
researchers and leaders in academia, industry, the non-profit
sector, and government to discuss the challenges and opportunities
facing those engaged in the research and development of
psychedelics for various health conditions with considerable unmet
need. The event will highlight the progress being made towards
regulatory approval of a variety of psychedelics with the potential
to treat various conditions, including inflammatory/autoimmune
disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches,
depression, and opioid use disorder. More information is available
at www.psychedelics-conference.com.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company under takes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024